Compare Sanofi SA (SNY) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs 22nd Century Group Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Sanofi SA is far larger — about 70355.7× 22nd Century Group Inc's market cap, and Sanofi SA pays a 5.5% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| SNY | XXII | |
|---|---|---|
Market Cap | $104.83B | $1.49M |
Sector | Health | Technology |
52-Week High | $52.34 | $1.07K |
52-Week Low | $41.33 | $3.90 |
Enterprise Value | $121.32B | -$6.74M |
Dividend Yield | 5.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
